PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1259077

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1259077

Saudi Arabia, Turkey, and Egypt Immunohematology Market - Industry Trends and Forecast to 2030

PUBLISHED: January 3, 2023

PAGES: 120 Pages

DELIVERY TIME: Inquiry

SELECT AN OPTION

Saudi Arabia, Turkey, and Egypt immunohematology market is projected to register a substantial CAGR of 3.8%, 4.2%, and 3.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Saudi Arabia, Turkey, and Egypt Immunohematology Market, By Product Type (Immunohematology Analyzer and Immunohematology Reagent), Technology (Microplates, Biochips, Gel cards, Erythrocyte- Magnetized Technology EMT, Polymerase Chain Reaction), Application (Antibody Screening and Blood Typing), End User (Blood Banks, Hospitals, Diagnostic and Reference Laboratories, Academic and Research Institutes), Distribution Channel (Direct Tender, Retail Sales and Third Party Distribution), Country (Saudi Arabia, Egypt and Turkey) Industry Trends and Forecast to 2030.

Increasing demand for blood and blood products

Technological advancements for development of new products

Market Players:

Some of the key market players operating in the Saudi Arabia, Turkey, and Egypt Immunohematology Market are listed below:

Abbott

Ortho Clinical Diagnostics.

Horiba Medical

Immucor, Inc.

Siemens Healthineers

Beckman Coulter, Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific Inc.

1 INTRODUCTION 12

1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF THE SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET 12
1.4 CURRENCY AND PRICING 14
1.5 LIMITATIONS 14
1.6 MARKETS COVERED 14

2 MARKET SEGMENTATION 16

2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.6 MULTIVARIATE MODELLING 23
2.7 MARKET APPLICATION COVERAGE GRID 24
2.8 PRODUCT LIFELINE CURVE 25
2.9 DBMR MARKET POSITION GRID 27
2.10 VENDOR SHARE ANALYSIS 28
2.11 SECONDARY SOURCES 29
2.12 ASSUMPTIONS 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 33

4.1 PESTEL ANALYSIS 36
4.2 PORTER'S FIVE FORCES 37

5 INDUSTRY INSIGHTS 38

5.1 PATENT ANALYSIS 38
5.2 DRUG TREATMENT RATE BY MATURED MARKETS 38
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 38
5.4 KEY PRICING STRATEGIES 39

6 REGULATORY GUIDELINES FOR IMMUNOHEMATOLOGY 41

6.1 REGULATIONS IN SAUDI ARABIA 41
6.2 REGULATIONS IN TURKEY 41
6.3 REGULATIONS IN EGYPT 42

7 MARKET OVERVIEW 43

7.1 DRIVERS 45
- 7.1.1 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS 45
- 7.1.2 TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS 45
- 7.1.3 INCREASING INCIDENCE OF TRAUMA AND IMMUNOHEMATOLOGICAL DISORDERS 45
7.2 RESTRAINTS 46
- 7.2.1 HIGH COST OF BLOOD TESTING AND TRANSFUSION 46
- 7.2.2 STRINGENT REGULATIONS FOR IMMUNOHEMATOLOGY TESTING IN SAUDI ARABIA, TURKEY, AND EGYPT 46
7.3 OPPORTUNITIES 47
- 7.3.1 RISING AWARENESS ABOUT BLOOD DONATION 47
- 7.3.2 RISING CASES OF BLOOD CANCER 47
7.4 CHALLENGES 48
- 7.4.1 RISK OF TRANSFUSION-TRANSMITTED INFECTIONS 48
- 7.4.2 LACK OF SKILLED PERSONNEL TO CARRY OUT IMMUNOHEMATOLOGY TESTING. 48

8 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE 49

8.1 OVERVIEW 50
8.2 IMMUNOHEMATOLOGY ANALYZER 57
8.3 IMMUNOHEMATOLOGY REAGENT 57

9 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY TECHNOLOGY 58

9.1 OVERVIEW 59
9.2 MICROPLATES 67
9.3 GEL CARDS 67
9.4 POLYMERASE CHAIN REACTION 67
9.5 ERYHTROCYTE-MAGNETIZED TECHNOLOGY (EMT) 67
9.6 OTHERS 68

10 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY APPLICATION 69

10.1 OVERVIEW 70
10.2 BLOOD TYPING 77
10.3 ANTIBODY SCREENING 77

11 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY END USER 78

11.1 OVERVIEW 79
11.2 BLOOD BANKS 86
11.3 HOSPITALS 86
11.4 DIAGNOSTIC AND REFERENCE LABORATORIES 86
11.5 ACADEMIC AND RESEARCH INSTITUTES 86

12 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY DISTRIBUTION CHANNEL 87

12.1 OVERVIEW 88
12.2 DIRECT SALES 95
12.3 THIRD PARTY DISTRIBUTION 95
12.4 RETAIL SALES 95

13 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, COMPANY LANDSCAPE 96

13.1 COMPANY SHARE ANALYSIS: TURKEY 96
13.2 COMPANY SHARE ANALYSIS: SAUDI ARABIA 97
13.3 COMPANY SHARE ANALYSIS: EGYPT 98

14 SWOT ANALYSIS 99

15 COMPANY PROFILE 100

15.1 ABBOTT 100
- 15.1.1 COMPANY SNAPSHOT 100
- 15.1.2 REVENUE ANALYSIS 100
- 15.1.3 PRODUCT PORTFOLIO 101
- 15.1.4 RECENT DEVELOPMENT 101
15.2 ORTHO CLINICAL DIAGNOSTICS 102
- 15.2.1 COMPANY SNAPSHOT 102
- 15.2.2 REVENUE ANALYSIS 102
- 15.2.3 PRODUCT PORTFOLIO 103
- 15.2.4 RECENT DEVELOPMENTS 103
15.3 SIEMENS HEALTHINEERS AG 104
- 15.3.1 COMPANY SNAPSHOT 104
- 15.3.2 REVENUE ANALYSIS 104
- 15.3.3 PRODUCT PORTFOLIO 105
- 15.3.4 RECENT DEVELOPMENTS 105
15.4 BECKMAN COULTER, INC. 106
- 15.4.1 COMPANY SNAPSHOT 106
- 15.4.2 REVNUE ANALYSIS 106
- 15.4.3 PRODUCT PORTFOLIO 107
- 15.4.4 RECENT DEVELOPMENT 107
15.5 HORIBA 108
- 15.5.1 COMPANY SNAPSHOT 108
- 15.5.2 REVENUE ANALYSIS 108
- 15.5.3 PRODUCT PORTFOLIO 109
- 15.5.4 RECENT DEVELOPMENTS 109
15.6 BIO RAD LABORATORIES, INC. 110
- 15.6.1 COMPANY SNAPSHOT 110
- 15.6.2 REVENUE ANALYSIS 110
- 15.6.3 PRODUCT PORTFOLIO 111
- 15.6.4 RECENT DEVELOPMENTS 111
15.7 IMMUCOR, INC. 112
- 15.7.1 COMPANY SNAPSHOT 112
- 15.7.2 PRODUCT PORTFOLIO 112
- 15.7.3 RECENT DEVELOPMENTS 112
15.8 MERCK KGAA 113
- 15.8.1 COMPANY SNAPSHOT 113
- 15.8.2 REVENUE ANALYSIS 113
- 15.8.3 PRODUCT PORTFOLIO 114
- 15.8.4 RECENT DEVELOPMENTS 114
15.9 THERMO FISCHER SCIENTIFIC INC. 115
- 15.9.1 COMPANY SNAPSHOT 115
- 15.9.2 REVENUE ANALYSIS 115
- 15.9.3 PRODUCT PORTFOLIO 116
- 15.9.4 RECENT DEVELOPMENTS 116

16 QUESTIONNAIRE 117

17 RELATED REPORTS 120

LIST OF TABLES

TABLE 1 THE PRICES FOR VARIOUS HEMATOLOGY ANALYZERS ARE GIVEN BELOW 39

LIST OF FIGURES

FIGURE 1 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: SEGMENTATION 16
FIGURE 2 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: DATA TRIANGULATION 18
FIGURE 3 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: DROC ANALYSIS 19
FIGURE 4 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 20
FIGURE 5 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: COMPANY RESEARCH ANALYSIS 21
FIGURE 6 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: INTERVIEW DEMOGRAPHICS 22
FIGURE 7 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: MARKET APPLICATION COVERAGE GRID 24
FIGURE 8 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: DBMR MARKET POSITION GRID 27
FIGURE 9 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: VENDOR SHARE ANALYSIS 28
FIGURE 10 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET: SEGMENTATION 32
FIGURE 11 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS AND TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS IS EXPECTED TO DRIVE THE GROWTH OF THE SAUDI ARABIA IMMUNOHEMATOLOGY MARKET FROM 2023 TO 2030 33
FIGURE 12 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS AND TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS IS EXPECTED TO DRIVE THE GROWTH OF THE TURKEY IMMUNOHEMATOLOGY MARKET FROM 2023 TO 2030 33
FIGURE 13 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS AND TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS IS EXPECTED TO DRIVE THE GROWTH OF THE EGYPT IMMUNOHEMATOLOGY MARKET FROM 2023 TO 2030 34
FIGURE 14 THE IMMUNOHEMATOLOGY ANALYZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA IMMUNOHEMATOLOGY MARKET IN 2023 & 2030 34
FIGURE 15 THE IMMUNOHEMATOLOGY ANALYZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE TURKEY IMMUNOHEMATOLOGY MARKET IN 2023 & 2030 35
FIGURE 16 THE IMMUNOHEMATOLOGY ANALYZER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EGYPT IMMUNOHEMATOLOGY MARKET IN 2023 & 2030 35
FIGURE 17 PATIENT FLOW DIAGRAM 40
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET 44
FIGURE 19 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2022 50
FIGURE 20 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2022 51
FIGURE 21 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2022 52
FIGURE 22 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2023-2030 (USD MILLION) 53
FIGURE 23 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2023-2030 (USD MILLION) 53
FIGURE 24 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, 2023-2030 (USD MILLION) 53
FIGURE 25 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, CAGR (2023-2030) 54
FIGURE 26 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, CAGR (2023-2030) 54
FIGURE 27 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, CAGR (2023-2030) 55
FIGURE 28 TURKEY IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, LIFELINE CURVE 55
FIGURE 29 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, LIFELINE CURVE 56
FIGURE 30 EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE, LIFELINE CURVE 56
FIGURE 31 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2022 59
FIGURE 32 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2022 60
FIGURE 33 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2022 61
FIGURE 34 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 62
FIGURE 35 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 62
FIGURE 36 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 63
FIGURE 37 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, CAGR (2023-2030) 63
FIGURE 38 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, CAGR (2023-2030) 64
FIGURE 39 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, CAGR (2023-2030) 64
FIGURE 40 TURKEY IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, LIFELINE CURVE 65
FIGURE 41 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, LIFELINE CURVE 65
FIGURE 42 EGYPT IMMUNOHEMATOLOGY MARKET: BY TECHNOLOGY, LIFELINE CURVE 66
FIGURE 43 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2022 70
FIGURE 44 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2022 71
FIGURE 45 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2022 72
FIGURE 46 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 72
FIGURE 47 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 73
FIGURE 48 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 73
FIGURE 49 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, CAGR (2023-2030) 74
FIGURE 50 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, CAGR (2023-2030) 74
FIGURE 51 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, CAGR (2023-2030) 75
FIGURE 52 TURKEY IMMUNOHEMATOLOGY MARKET: BY APPLICATION, LIFELINE CURVE 75
FIGURE 53 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY APPLICATION, LIFELINE CURVE 76
FIGURE 54 EGYPT IMMUNOHEMATOLOGY MARKET: BY APPLICATION, LIFELINE CURVE 76
FIGURE 55 TUKEY IMMUNOHEMATOLOGY MARKET: BY END USER, 2022 79
FIGURE 56 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, 2022 80
FIGURE 57 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, 2022 81
FIGURE 58 TURKEY IMMUNOHEMATOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION) 81
FIGURE 59 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION) 82
FIGURE 60 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION) 82
FIGURE 61 TURKEY IMMUNOHEMATOLOGY MARKET: BY END USER, CAGR (2023-2030) 83
FIGURE 62 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, CAGR (2023-2030) 83
FIGURE 63 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, CAGR (2023-2030) 84
FIGURE 64 TURKEY IMMUNOHEMATOLOGY MARKET: BY END USER, LIFELINE CURVE 84
FIGURE 65 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY END USER, LIFELINE CURVE 85
FIGURE 66 EGYPT IMMUNOHEMATOLOGY MARKET: BY END USER, LIFELINE CURVE 85
FIGURE 67 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022 88
FIGURE 68 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022 89
FIGURE 69 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022 90
FIGURE 70 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 91
FIGURE 71 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 91
FIGURE 72 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 91
FIGURE 73 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 92
FIGURE 74 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 92
FIGURE 75 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 93
FIGURE 76 TURKEY IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 93
FIGURE 77 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 78 EGYPT IMMUNOHEMATOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 79 TURKEY IMMUNOHEMATOLOGY MARKET: COMPANY SHARE 2022 (%) 96
FIGURE 80 SAUDI ARABIA IMMUNOHEMATOLOGY MARKET: COMPANY SHARE 2022 (%) 97
FIGURE 81 EGYPT IMMUNOHEMATOLOGY MARKET: COMPANY SHARE 2022 (%) 98

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ